FDA Objects To Claims Based On Retrospective Analysis In BenzaClin Letter
Executive Summary
Sponsors should be wary of constructing advertising claims that move beyond the primary findings of a clinical trial
You may also be interested in...
Healthiness Of Actors In DTC Spots Returns As Issue As FDA Cites Aricept Ads
Pfizer, which co-markets the Alzheimer's treatment with Eisai, could feel the biggest impact of the notice of violation due to its settlement with state attorneys general.
Watching Your Language: FDA Ad Division Objects To User-Friendly Efficacy Claims With Jargon-y Risk Info
FDA expects drug advertisements to use the same level of language to convey both safety and efficacy information, according to a pair of letters from the Division of Drug Marketing, Advertising and Communications
Watching Your Language: FDA Ad Division Objects To User-Friendly Efficacy Claims With Jargon-y Risk Info
FDA expects drug advertisements to use the same level of language to convey both safety and efficacy information, according to a pair of letters from the Division of Drug Marketing, Advertising and Communications